Rapid assessment of avoidable blindness-based healthcare costs of diabetic retinopathy in Hungary and its projection for the year 2045.
CONCLUSIONS: The cost per patient for treating DR was lower in Hungary than in other countries. Due to the increasing socioeconomic burden of proliferative DR and diabetes-related blindness, it would be important to invest in DR screening, prevention and early treatment. Our new RAAB-based cost of DR model may facilitate comparisons of DR treatment costs across countries.
PMID: 32788328 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tóth G, Limburg H, Szabó D, Sándor GL, Nagy ZZ, Németh J Tags: Br J Ophthalmol Source Type: research
More News: Blindness | Diabetes | Diabetes Mellitus | Endocrinology | Healthcare Costs | Hungary Health | Opthalmology | Scotland Health | Study | UK Health